nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR1B—trigeminal nucleus—multiple sclerosis	0.0423	0.109	CbGeAlD
Loxapine—HTR1D—trigeminal nucleus—multiple sclerosis	0.0409	0.106	CbGeAlD
Loxapine—HTR3A—area postrema—multiple sclerosis	0.0371	0.0961	CbGeAlD
Loxapine—HTR1D—meninx—multiple sclerosis	0.0272	0.0703	CbGeAlD
Loxapine—HTR2A—trigeminal nucleus—multiple sclerosis	0.0203	0.0526	CbGeAlD
Loxapine—HTR1B—trigeminal nerve—multiple sclerosis	0.0111	0.0287	CbGeAlD
Loxapine—HTR1D—trigeminal nerve—multiple sclerosis	0.0107	0.0278	CbGeAlD
Loxapine—HTR7—pons—multiple sclerosis	0.00603	0.0156	CbGeAlD
Loxapine—HTR2A—trigeminal nerve—multiple sclerosis	0.00534	0.0138	CbGeAlD
Loxapine—DRD1—nerve—multiple sclerosis	0.005	0.0129	CbGeAlD
Loxapine—HTR3A—nerve—multiple sclerosis	0.00483	0.0125	CbGeAlD
Loxapine—HTR5A—nervous system—multiple sclerosis	0.00452	0.0117	CbGeAlD
Loxapine—HTR5A—central nervous system—multiple sclerosis	0.00435	0.0112	CbGeAlD
Loxapine—SLC6A3—nerve—multiple sclerosis	0.00402	0.0104	CbGeAlD
Loxapine—HTR7—peripheral nervous system—multiple sclerosis	0.00401	0.0104	CbGeAlD
Loxapine—HTR2A—pons—multiple sclerosis	0.00376	0.00972	CbGeAlD
Loxapine—HTR1E—brainstem—multiple sclerosis	0.00368	0.00952	CbGeAlD
Loxapine—HTR5A—brain—multiple sclerosis	0.00345	0.00893	CbGeAlD
Loxapine—SLC6A2—nerve—multiple sclerosis	0.00324	0.00839	CbGeAlD
Loxapine—HTR7—nerve—multiple sclerosis	0.00313	0.00809	CbGeAlD
Loxapine—DRD2—nerve—multiple sclerosis	0.00296	0.00765	CbGeAlD
Loxapine—ADRA2A—peripheral nervous system—multiple sclerosis	0.00294	0.00761	CbGeAlD
Loxapine—HTR2A—pineal body—multiple sclerosis	0.00268	0.00694	CbGeAlD
Loxapine—HTR2A—peripheral nervous system—multiple sclerosis	0.0025	0.00647	CbGeAlD
Loxapine—DRD1—brainstem—multiple sclerosis	0.00215	0.00556	CbGeAlD
Loxapine—HTR3A—brainstem—multiple sclerosis	0.00207	0.00537	CbGeAlD
Loxapine—HTR2A—nerve—multiple sclerosis	0.00195	0.00504	CbGeAlD
Loxapine—HTR1E—nervous system—multiple sclerosis	0.00193	0.00499	CbGeAlD
Loxapine—HTR1E—central nervous system—multiple sclerosis	0.00186	0.0048	CbGeAlD
Loxapine—HTR1B—brainstem—multiple sclerosis	0.00174	0.0045	CbGeAlD
Loxapine—SLC6A3—brainstem—multiple sclerosis	0.00173	0.00446	CbGeAlD
Loxapine—DRD4—brain—multiple sclerosis	0.00171	0.00442	CbGeAlD
Loxapine—CHRM4—nervous system—multiple sclerosis	0.00169	0.00437	CbGeAlD
Loxapine—HTR1D—brainstem—multiple sclerosis	0.00168	0.00436	CbGeAlD
Loxapine—HTR2C—brainstem—multiple sclerosis	0.00167	0.00432	CbGeAlD
Loxapine—CHRM4—central nervous system—multiple sclerosis	0.00163	0.00421	CbGeAlD
Loxapine—SLC6A4—brainstem—multiple sclerosis	0.00158	0.00409	CbGeAlD
Loxapine—DRD3—nervous system—multiple sclerosis	0.00157	0.00407	CbGeAlD
Loxapine—DRD3—central nervous system—multiple sclerosis	0.00151	0.00391	CbGeAlD
Loxapine—HTR6—nervous system—multiple sclerosis	0.00151	0.00391	CbGeAlD
Loxapine—HTR1E—brain—multiple sclerosis	0.00147	0.00381	CbGeAlD
Loxapine—DRD5—nervous system—multiple sclerosis	0.00147	0.00381	CbGeAlD
Loxapine—HTR6—central nervous system—multiple sclerosis	0.00146	0.00377	CbGeAlD
Loxapine—DRD5—central nervous system—multiple sclerosis	0.00142	0.00367	CbGeAlD
Loxapine—HTR1A—brainstem—multiple sclerosis	0.0014	0.00363	CbGeAlD
Loxapine—SLC6A2—brainstem—multiple sclerosis	0.00139	0.0036	CbGeAlD
Loxapine—HRH2—nervous system—multiple sclerosis	0.00138	0.00358	CbGeAlD
Loxapine—DRD1—midbrain—multiple sclerosis	0.00137	0.00354	CbGeAlD
Loxapine—HTR7—brainstem—multiple sclerosis	0.00134	0.00347	CbGeAlD
Loxapine—HRH2—central nervous system—multiple sclerosis	0.00133	0.00344	CbGeAlD
Loxapine—CHRM5—nervous system—multiple sclerosis	0.00132	0.00342	CbGeAlD
Loxapine—ADRA1A—brainstem—multiple sclerosis	0.00129	0.00335	CbGeAlD
Loxapine—CHRM4—brain—multiple sclerosis	0.00129	0.00334	CbGeAlD
Loxapine—CHRM5—central nervous system—multiple sclerosis	0.00127	0.00329	CbGeAlD
Loxapine—DRD2—brainstem—multiple sclerosis	0.00127	0.00328	CbGeAlD
Loxapine—DRD2—retina—multiple sclerosis	0.00122	0.00317	CbGeAlD
Loxapine—ADRA1B—nervous system—multiple sclerosis	0.00121	0.00312	CbGeAlD
Loxapine—DRD3—brain—multiple sclerosis	0.0012	0.00311	CbGeAlD
Loxapine—HTR2C—medulla oblongata—multiple sclerosis	0.00116	0.00301	CbGeAlD
Loxapine—ADRA1B—central nervous system—multiple sclerosis	0.00116	0.00301	CbGeAlD
Loxapine—HTR6—brain—multiple sclerosis	0.00116	0.00299	CbGeAlD
Loxapine—DRD5—brain—multiple sclerosis	0.00113	0.00291	CbGeAlD
Loxapine—DRD1—nervous system—multiple sclerosis	0.00113	0.00291	CbGeAlD
Loxapine—HTR1B—midbrain—multiple sclerosis	0.00111	0.00287	CbGeAlD
Loxapine—SLC6A3—midbrain—multiple sclerosis	0.0011	0.00285	CbGeAlD
Loxapine—HTR3A—nervous system—multiple sclerosis	0.00109	0.00281	CbGeAlD
Loxapine—DRD1—central nervous system—multiple sclerosis	0.00108	0.0028	CbGeAlD
Loxapine—HTR1B—spinal cord—multiple sclerosis	0.00108	0.0028	CbGeAlD
Loxapine—HTR1D—midbrain—multiple sclerosis	0.00107	0.00278	CbGeAlD
Loxapine—SLC6A3—spinal cord—multiple sclerosis	0.00107	0.00278	CbGeAlD
Loxapine—HTR2C—midbrain—multiple sclerosis	0.00106	0.00275	CbGeAlD
Loxapine—HRH2—brain—multiple sclerosis	0.00106	0.00273	CbGeAlD
Loxapine—HTR3A—central nervous system—multiple sclerosis	0.00105	0.00271	CbGeAlD
Loxapine—HTR2C—spinal cord—multiple sclerosis	0.00104	0.00268	CbGeAlD
Loxapine—CHRM5—brain—multiple sclerosis	0.00101	0.00261	CbGeAlD
Loxapine—SLC6A4—midbrain—multiple sclerosis	0.00101	0.00261	CbGeAlD
Loxapine—Agranulocytosis—Mitoxantrone—multiple sclerosis	0.000997	0.00417	CcSEcCtD
Loxapine—SLC6A4—spinal cord—multiple sclerosis	0.000983	0.00254	CbGeAlD
Loxapine—SLC6A2—medulla oblongata—multiple sclerosis	0.000971	0.00251	CbGeAlD
Loxapine—Hypotension—Cladribine—multiple sclerosis	0.000969	0.00405	CcSEcCtD
Loxapine—Hepatitis—Mitoxantrone—multiple sclerosis	0.000959	0.00401	CcSEcCtD
Loxapine—Insomnia—Cladribine—multiple sclerosis	0.000937	0.00392	CcSEcCtD
Loxapine—HTR7—medulla oblongata—multiple sclerosis	0.000936	0.00242	CbGeAlD
Loxapine—Paraesthesia—Cladribine—multiple sclerosis	0.000931	0.00389	CcSEcCtD
Loxapine—Psychotic disorder—Betamethasone—multiple sclerosis	0.000927	0.00388	CcSEcCtD
Loxapine—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000927	0.00388	CcSEcCtD
Loxapine—Leukopenia—Azathioprine—multiple sclerosis	0.000924	0.00387	CcSEcCtD
Loxapine—Dyspnoea—Cladribine—multiple sclerosis	0.000924	0.00386	CcSEcCtD
Loxapine—ADRA1B—brain—multiple sclerosis	0.000923	0.00239	CbGeAlD
Loxapine—Somnolence—Cladribine—multiple sclerosis	0.000921	0.00385	CcSEcCtD
Loxapine—HTR1B—nervous system—multiple sclerosis	0.000912	0.00236	CbGeAlD
Loxapine—CHRM2—nervous system—multiple sclerosis	0.000907	0.00235	CbGeAlD
Loxapine—SLC6A3—nervous system—multiple sclerosis	0.000904	0.00234	CbGeAlD
Loxapine—HTR1A—midbrain—multiple sclerosis	0.000895	0.00232	CbGeAlD
Loxapine—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000895	0.00374	CcSEcCtD
Loxapine—Weight increased—Prednisolone—multiple sclerosis	0.000895	0.00374	CcSEcCtD
Loxapine—Fatigue—Cladribine—multiple sclerosis	0.000894	0.00374	CcSEcCtD
Loxapine—Bronchospasm—Methylprednisolone—multiple sclerosis	0.000887	0.00371	CcSEcCtD
Loxapine—Constipation—Cladribine—multiple sclerosis	0.000886	0.00371	CcSEcCtD
Loxapine—HTR1D—nervous system—multiple sclerosis	0.000883	0.00228	CbGeAlD
Loxapine—HTR1B—central nervous system—multiple sclerosis	0.000878	0.00227	CbGeAlD
Loxapine—HTR2C—nervous system—multiple sclerosis	0.000874	0.00226	CbGeAlD
Loxapine—HTR1A—spinal cord—multiple sclerosis	0.000873	0.00226	CbGeAlD
Loxapine—CHRM2—central nervous system—multiple sclerosis	0.000873	0.00226	CbGeAlD
Loxapine—SLC6A3—central nervous system—multiple sclerosis	0.000871	0.00225	CbGeAlD
Loxapine—ADRA2C—medulla oblongata—multiple sclerosis	0.00086	0.00223	CbGeAlD
Loxapine—DRD1—brain—multiple sclerosis	0.00086	0.00222	CbGeAlD
Loxapine—ADRB1—nervous system—multiple sclerosis	0.000858	0.00222	CbGeAlD
Loxapine—HTR7—midbrain—multiple sclerosis	0.000855	0.00221	CbGeAlD
Loxapine—Feeling abnormal—Cladribine—multiple sclerosis	0.000854	0.00357	CcSEcCtD
Loxapine—Gynaecomastia—Methotrexate—multiple sclerosis	0.000851	0.00356	CcSEcCtD
Loxapine—SLC6A3—cerebellum—multiple sclerosis	0.000851	0.0022	CbGeAlD
Loxapine—HTR1D—central nervous system—multiple sclerosis	0.00085	0.0022	CbGeAlD
Loxapine—Alopecia—Mitoxantrone—multiple sclerosis	0.000847	0.00354	CcSEcCtD
Loxapine—HTR2C—central nervous system—multiple sclerosis	0.000842	0.00218	CbGeAlD
Loxapine—HTR2A—brainstem—multiple sclerosis	0.000837	0.00216	CbGeAlD
Loxapine—HTR7—spinal cord—multiple sclerosis	0.000834	0.00216	CbGeAlD
Loxapine—HTR3A—brain—multiple sclerosis	0.000831	0.00215	CbGeAlD
Loxapine—SLC6A4—nervous system—multiple sclerosis	0.000829	0.00214	CbGeAlD
Loxapine—ADRB1—central nervous system—multiple sclerosis	0.000826	0.00214	CbGeAlD
Loxapine—CHRM1—nervous system—multiple sclerosis	0.000825	0.00214	CbGeAlD
Loxapine—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000825	0.00345	CcSEcCtD
Loxapine—Weight increased—Triamcinolone—multiple sclerosis	0.000823	0.00344	CcSEcCtD
Loxapine—Weight increased—Methylprednisolone—multiple sclerosis	0.000821	0.00343	CcSEcCtD
Loxapine—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000817	0.00342	CcSEcCtD
Loxapine—DRD2—midbrain—multiple sclerosis	0.000809	0.00209	CbGeAlD
Loxapine—HTR2A—retina—multiple sclerosis	0.000807	0.00209	CbGeAlD
Loxapine—Psychotic disorder—Prednisone—multiple sclerosis	0.000807	0.00338	CcSEcCtD
Loxapine—SLC6A4—central nervous system—multiple sclerosis	0.000798	0.00206	CbGeAlD
Loxapine—CHRM1—central nervous system—multiple sclerosis	0.000795	0.00206	CbGeAlD
Loxapine—Hypotension—Azathioprine—multiple sclerosis	0.000788	0.00329	CcSEcCtD
Loxapine—Vision blurred—Mitoxantrone—multiple sclerosis	0.000787	0.00329	CcSEcCtD
Loxapine—Photosensitivity—Methotrexate—multiple sclerosis	0.000787	0.00329	CcSEcCtD
Loxapine—ADRA2C—midbrain—multiple sclerosis	0.000786	0.00203	CbGeAlD
Loxapine—ADRA2C—spinal cord—multiple sclerosis	0.000767	0.00198	CbGeAlD
Loxapine—Hypersensitivity—Cladribine—multiple sclerosis	0.000764	0.00319	CcSEcCtD
Loxapine—Leukopenia—Mitoxantrone—multiple sclerosis	0.000747	0.00313	CcSEcCtD
Loxapine—Weight increased—Dexamethasone—multiple sclerosis	0.000746	0.00312	CcSEcCtD
Loxapine—Weight increased—Betamethasone—multiple sclerosis	0.000746	0.00312	CcSEcCtD
Loxapine—Asthenia—Cladribine—multiple sclerosis	0.000744	0.00311	CcSEcCtD
Loxapine—Weight decreased—Dexamethasone—multiple sclerosis	0.000742	0.0031	CcSEcCtD
Loxapine—Weight decreased—Betamethasone—multiple sclerosis	0.000742	0.0031	CcSEcCtD
Loxapine—CHRM3—nervous system—multiple sclerosis	0.000739	0.00191	CbGeAlD
Loxapine—HTR1A—nervous system—multiple sclerosis	0.000736	0.0019	CbGeAlD
Loxapine—Pruritus—Cladribine—multiple sclerosis	0.000733	0.00307	CcSEcCtD
Loxapine—SLC6A2—nervous system—multiple sclerosis	0.00073	0.00189	CbGeAlD
Loxapine—Cough—Mitoxantrone—multiple sclerosis	0.000728	0.00305	CcSEcCtD
Loxapine—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000728	0.00304	CcSEcCtD
Loxapine—Convulsion—Mitoxantrone—multiple sclerosis	0.000723	0.00302	CcSEcCtD
Loxapine—Hypertension—Mitoxantrone—multiple sclerosis	0.000721	0.00301	CcSEcCtD
Loxapine—CHRM3—central nervous system—multiple sclerosis	0.000711	0.00184	CbGeAlD
Loxapine—Chest pain—Mitoxantrone—multiple sclerosis	0.000711	0.00297	CcSEcCtD
Loxapine—HTR1A—central nervous system—multiple sclerosis	0.000708	0.00183	CbGeAlD
Loxapine—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.000705	0.00295	CcSEcCtD
Loxapine—HTR7—nervous system—multiple sclerosis	0.000703	0.00182	CbGeAlD
Loxapine—SLC6A2—central nervous system—multiple sclerosis	0.000702	0.00182	CbGeAlD
Loxapine—HTR1B—brain—multiple sclerosis	0.000697	0.0018	CbGeAlD
Loxapine—Feeling abnormal—Azathioprine—multiple sclerosis	0.000695	0.0029	CcSEcCtD
Loxapine—CHRM2—brain—multiple sclerosis	0.000693	0.00179	CbGeAlD
Loxapine—HTR1A—cerebellum—multiple sclerosis	0.000692	0.00179	CbGeAlD
Loxapine—SLC6A3—brain—multiple sclerosis	0.000691	0.00179	CbGeAlD
Loxapine—Confusional state—Mitoxantrone—multiple sclerosis	0.000687	0.00287	CcSEcCtD
Loxapine—ADRA2A—medulla oblongata—multiple sclerosis	0.000686	0.00178	CbGeAlD
Loxapine—Dizziness—Cladribine—multiple sclerosis	0.000685	0.00287	CcSEcCtD
Loxapine—Oedema—Mitoxantrone—multiple sclerosis	0.000681	0.00285	CcSEcCtD
Loxapine—ADRA1A—nervous system—multiple sclerosis	0.000678	0.00175	CbGeAlD
Loxapine—HTR7—central nervous system—multiple sclerosis	0.000677	0.00175	CbGeAlD
Loxapine—HTR1D—brain—multiple sclerosis	0.000675	0.00175	CbGeAlD
Loxapine—Shock—Mitoxantrone—multiple sclerosis	0.00067	0.0028	CcSEcCtD
Loxapine—HTR2C—brain—multiple sclerosis	0.000668	0.00173	CbGeAlD
Loxapine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000667	0.00279	CcSEcCtD
Loxapine—Tachycardia—Mitoxantrone—multiple sclerosis	0.000665	0.00278	CcSEcCtD
Loxapine—DRD2—nervous system—multiple sclerosis	0.000665	0.00172	CbGeAlD
Loxapine—HTR7—cerebellum—multiple sclerosis	0.000662	0.00171	CbGeAlD
Loxapine—Vomiting—Cladribine—multiple sclerosis	0.000659	0.00276	CcSEcCtD
Loxapine—ADRB1—brain—multiple sclerosis	0.000656	0.0017	CbGeAlD
Loxapine—Angiopathy—Methylprednisolone—multiple sclerosis	0.000655	0.00274	CcSEcCtD
Loxapine—Rash—Cladribine—multiple sclerosis	0.000654	0.00273	CcSEcCtD
Loxapine—ADRA1A—central nervous system—multiple sclerosis	0.000653	0.00169	CbGeAlD
Loxapine—Dermatitis—Cladribine—multiple sclerosis	0.000653	0.00273	CcSEcCtD
Loxapine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000651	0.00272	CcSEcCtD
Loxapine—Weight increased—Prednisone—multiple sclerosis	0.00065	0.00272	CcSEcCtD
Loxapine—Headache—Cladribine—multiple sclerosis	0.000649	0.00272	CcSEcCtD
Loxapine—ADRA2C—nervous system—multiple sclerosis	0.000646	0.00167	CbGeAlD
Loxapine—Weight decreased—Prednisone—multiple sclerosis	0.000646	0.0027	CcSEcCtD
Loxapine—Vision blurred—Prednisolone—multiple sclerosis	0.000645	0.0027	CcSEcCtD
Loxapine—DRD2—central nervous system—multiple sclerosis	0.00064	0.00166	CbGeAlD
Loxapine—ADRA1A—cerebellum—multiple sclerosis	0.000638	0.00165	CbGeAlD
Loxapine—Hypotension—Mitoxantrone—multiple sclerosis	0.000637	0.00266	CcSEcCtD
Loxapine—SLC6A4—brain—multiple sclerosis	0.000633	0.00164	CbGeAlD
Loxapine—CHRM1—brain—multiple sclerosis	0.000631	0.00163	CbGeAlD
Loxapine—ADRA2A—midbrain—multiple sclerosis	0.000627	0.00162	CbGeAlD
Loxapine—DRD2—cerebellum—multiple sclerosis	0.000626	0.00162	CbGeAlD
Loxapine—ADRA2C—central nervous system—multiple sclerosis	0.000622	0.00161	CbGeAlD
Loxapine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000621	0.0026	CcSEcCtD
Loxapine—Dysgeusia—Triamcinolone—multiple sclerosis	0.000617	0.00258	CcSEcCtD
Loxapine—Nausea—Cladribine—multiple sclerosis	0.000616	0.00257	CcSEcCtD
Loxapine—Syncope—Prednisolone—multiple sclerosis	0.000614	0.00257	CcSEcCtD
Loxapine—ADRA2A—spinal cord—multiple sclerosis	0.000612	0.00158	CbGeAlD
Loxapine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000612	0.00256	CcSEcCtD
Loxapine—ADRA2C—cerebellum—multiple sclerosis	0.000608	0.00157	CbGeAlD
Loxapine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000607	0.00254	CcSEcCtD
Loxapine—Somnolence—Mitoxantrone—multiple sclerosis	0.000606	0.00253	CcSEcCtD
Loxapine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000602	0.00252	CcSEcCtD
Loxapine—Angiopathy—Dexamethasone—multiple sclerosis	0.000596	0.00249	CcSEcCtD
Loxapine—Angiopathy—Betamethasone—multiple sclerosis	0.000596	0.00249	CcSEcCtD
Loxapine—Convulsion—Prednisolone—multiple sclerosis	0.000593	0.00248	CcSEcCtD
Loxapine—Hypertension—Prednisolone—multiple sclerosis	0.000591	0.00247	CcSEcCtD
Loxapine—Fatigue—Mitoxantrone—multiple sclerosis	0.000587	0.00246	CcSEcCtD
Loxapine—HTR2A—medulla oblongata—multiple sclerosis	0.000584	0.00151	CbGeAlD
Loxapine—Constipation—Mitoxantrone—multiple sclerosis	0.000583	0.00244	CcSEcCtD
Loxapine—Alopecia—Betamethasone—multiple sclerosis	0.00058	0.00243	CcSEcCtD
Loxapine—Alopecia—Dexamethasone—multiple sclerosis	0.00058	0.00243	CcSEcCtD
Loxapine—Syncope—Triamcinolone—multiple sclerosis	0.000565	0.00236	CcSEcCtD
Loxapine—CHRM3—brain—multiple sclerosis	0.000565	0.00146	CbGeAlD
Loxapine—Syncope—Methylprednisolone—multiple sclerosis	0.000564	0.00236	CcSEcCtD
Loxapine—HTR1A—brain—multiple sclerosis	0.000562	0.00145	CbGeAlD
Loxapine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000561	0.00235	CcSEcCtD
Loxapine—Oedema—Prednisolone—multiple sclerosis	0.000559	0.00234	CcSEcCtD
Loxapine—SLC6A2—brain—multiple sclerosis	0.000558	0.00144	CbGeAlD
Loxapine—Dizziness—Azathioprine—multiple sclerosis	0.000557	0.00233	CcSEcCtD
Loxapine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000554	0.00232	CcSEcCtD
Loxapine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000552	0.00231	CcSEcCtD
Loxapine—Shock—Prednisolone—multiple sclerosis	0.00055	0.0023	CcSEcCtD
Loxapine—Cough—Triamcinolone—multiple sclerosis	0.00055	0.0023	CcSEcCtD
Loxapine—Convulsion—Triamcinolone—multiple sclerosis	0.000546	0.00228	CcSEcCtD
Loxapine—Tachycardia—Prednisolone—multiple sclerosis	0.000546	0.00228	CcSEcCtD
Loxapine—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000545	0.00228	CcSEcCtD
Loxapine—Convulsion—Methylprednisolone—multiple sclerosis	0.000544	0.00228	CcSEcCtD
Loxapine—Hypertension—Triamcinolone—multiple sclerosis	0.000544	0.00227	CcSEcCtD
Loxapine—Hypertension—Methylprednisolone—multiple sclerosis	0.000543	0.00227	CcSEcCtD
Loxapine—HTR7—brain—multiple sclerosis	0.000537	0.00139	CbGeAlD
Loxapine—Vomiting—Azathioprine—multiple sclerosis	0.000536	0.00224	CcSEcCtD
Loxapine—HTR2A—midbrain—multiple sclerosis	0.000533	0.00138	CbGeAlD
Loxapine—Drowsiness—Methotrexate—multiple sclerosis	0.000532	0.00223	CcSEcCtD
Loxapine—Rash—Azathioprine—multiple sclerosis	0.000531	0.00222	CcSEcCtD
Loxapine—Dermatitis—Azathioprine—multiple sclerosis	0.000531	0.00222	CcSEcCtD
Loxapine—Headache—Azathioprine—multiple sclerosis	0.000528	0.00221	CcSEcCtD
Loxapine—HRH1—nervous system—multiple sclerosis	0.000525	0.00136	CbGeAlD
Loxapine—Dry mouth—Triamcinolone—multiple sclerosis	0.000524	0.00219	CcSEcCtD
Loxapine—Renal failure—Methotrexate—multiple sclerosis	0.000523	0.00219	CcSEcCtD
Loxapine—HTR2A—spinal cord—multiple sclerosis	0.00052	0.00135	CbGeAlD
Loxapine—Angiopathy—Prednisone—multiple sclerosis	0.000519	0.00217	CcSEcCtD
Loxapine—ADRA1A—brain—multiple sclerosis	0.000518	0.00134	CbGeAlD
Loxapine—Confusional state—Methylprednisolone—multiple sclerosis	0.000517	0.00216	CcSEcCtD
Loxapine—ADRA2A—nervous system—multiple sclerosis	0.000516	0.00133	CbGeAlD
Loxapine—Oedema—Triamcinolone—multiple sclerosis	0.000514	0.00215	CcSEcCtD
Loxapine—Syncope—Dexamethasone—multiple sclerosis	0.000512	0.00214	CcSEcCtD
Loxapine—Syncope—Betamethasone—multiple sclerosis	0.000512	0.00214	CcSEcCtD
Loxapine—DRD2—brain—multiple sclerosis	0.000508	0.00131	CbGeAlD
Loxapine—Shock—Triamcinolone—multiple sclerosis	0.000506	0.00212	CcSEcCtD
Loxapine—Insomnia—Prednisolone—multiple sclerosis	0.000506	0.00211	CcSEcCtD
Loxapine—HRH1—central nervous system—multiple sclerosis	0.000505	0.00131	CbGeAlD
Loxapine—Alopecia—Prednisone—multiple sclerosis	0.000505	0.00211	CcSEcCtD
Loxapine—Shock—Methylprednisolone—multiple sclerosis	0.000505	0.00211	CcSEcCtD
Loxapine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000503	0.0021	CcSEcCtD
Loxapine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000502	0.0021	CcSEcCtD
Loxapine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000502	0.0021	CcSEcCtD
Loxapine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000502	0.0021	CcSEcCtD
Loxapine—Paraesthesia—Prednisolone—multiple sclerosis	0.000502	0.0021	CcSEcCtD
Loxapine—Tachycardia—Triamcinolone—multiple sclerosis	0.000502	0.0021	CcSEcCtD
Loxapine—Nausea—Azathioprine—multiple sclerosis	0.000501	0.00209	CcSEcCtD
Loxapine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000501	0.00209	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000497	0.00208	CcSEcCtD
Loxapine—ADRA2A—central nervous system—multiple sclerosis	0.000496	0.00128	CbGeAlD
Loxapine—Convulsion—Betamethasone—multiple sclerosis	0.000495	0.00207	CcSEcCtD
Loxapine—Convulsion—Dexamethasone—multiple sclerosis	0.000495	0.00207	CcSEcCtD
Loxapine—ADRA2C—brain—multiple sclerosis	0.000494	0.00128	CbGeAlD
Loxapine—Hypertension—Betamethasone—multiple sclerosis	0.000493	0.00206	CcSEcCtD
Loxapine—Hypertension—Dexamethasone—multiple sclerosis	0.000493	0.00206	CcSEcCtD
Loxapine—Asthenia—Mitoxantrone—multiple sclerosis	0.000489	0.00204	CcSEcCtD
Loxapine—ADRA2A—cerebellum—multiple sclerosis	0.000485	0.00126	CbGeAlD
Loxapine—Hypotension—Methylprednisolone—multiple sclerosis	0.000479	0.002	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—multiple sclerosis	0.000478	0.002	CcSEcCtD
Loxapine—Vision blurred—Prednisone—multiple sclerosis	0.000469	0.00196	CcSEcCtD
Loxapine—Oedema—Betamethasone—multiple sclerosis	0.000466	0.00195	CcSEcCtD
Loxapine—Oedema—Dexamethasone—multiple sclerosis	0.000466	0.00195	CcSEcCtD
Loxapine—Insomnia—Triamcinolone—multiple sclerosis	0.000465	0.00194	CcSEcCtD
Loxapine—Insomnia—Methylprednisolone—multiple sclerosis	0.000464	0.00194	CcSEcCtD
Loxapine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000462	0.00193	CcSEcCtD
Loxapine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000461	0.00193	CcSEcCtD
Loxapine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000461	0.00193	CcSEcCtD
Loxapine—Shock—Betamethasone—multiple sclerosis	0.000459	0.00192	CcSEcCtD
Loxapine—Shock—Dexamethasone—multiple sclerosis	0.000459	0.00192	CcSEcCtD
Loxapine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000458	0.00192	CcSEcCtD
Loxapine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000457	0.00191	CcSEcCtD
Loxapine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000457	0.00191	CcSEcCtD
Loxapine—Agitation—Prednisone—multiple sclerosis	0.000457	0.00191	CcSEcCtD
Loxapine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000457	0.00191	CcSEcCtD
Loxapine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000457	0.00191	CcSEcCtD
Loxapine—Tachycardia—Betamethasone—multiple sclerosis	0.000455	0.0019	CcSEcCtD
Loxapine—Tachycardia—Dexamethasone—multiple sclerosis	0.000455	0.0019	CcSEcCtD
Loxapine—Syncope—Prednisone—multiple sclerosis	0.000446	0.00187	CcSEcCtD
Loxapine—Fatigue—Triamcinolone—multiple sclerosis	0.000443	0.00185	CcSEcCtD
Loxapine—Fatigue—Methylprednisolone—multiple sclerosis	0.000442	0.00185	CcSEcCtD
Loxapine—HTR2A—nervous system—multiple sclerosis	0.000438	0.00113	CbGeAlD
Loxapine—Loss of consciousness—Prednisone—multiple sclerosis	0.000437	0.00183	CcSEcCtD
Loxapine—Hypotension—Betamethasone—multiple sclerosis	0.000436	0.00182	CcSEcCtD
Loxapine—Hypotension—Dexamethasone—multiple sclerosis	0.000436	0.00182	CcSEcCtD
Loxapine—Angiopathy—Methotrexate—multiple sclerosis	0.000433	0.00181	CcSEcCtD
Loxapine—Vomiting—Mitoxantrone—multiple sclerosis	0.000433	0.00181	CcSEcCtD
Loxapine—Convulsion—Prednisone—multiple sclerosis	0.000431	0.0018	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000431	0.0018	CcSEcCtD
Loxapine—Hypertension—Prednisone—multiple sclerosis	0.00043	0.0018	CcSEcCtD
Loxapine—Rash—Mitoxantrone—multiple sclerosis	0.00043	0.0018	CcSEcCtD
Loxapine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000429	0.00179	CcSEcCtD
Loxapine—Headache—Mitoxantrone—multiple sclerosis	0.000427	0.00179	CcSEcCtD
Loxapine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000424	0.00177	CcSEcCtD
Loxapine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000423	0.00177	CcSEcCtD
Loxapine—Alopecia—Methotrexate—multiple sclerosis	0.000422	0.00177	CcSEcCtD
Loxapine—HTR2A—central nervous system—multiple sclerosis	0.000422	0.00109	CbGeAlD
Loxapine—Insomnia—Betamethasone—multiple sclerosis	0.000422	0.00176	CcSEcCtD
Loxapine—Insomnia—Dexamethasone—multiple sclerosis	0.000422	0.00176	CcSEcCtD
Loxapine—Paraesthesia—Betamethasone—multiple sclerosis	0.000419	0.00175	CcSEcCtD
Loxapine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000419	0.00175	CcSEcCtD
Loxapine—HTR2A—cerebellum—multiple sclerosis	0.000413	0.00107	CbGeAlD
Loxapine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000412	0.00172	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—multiple sclerosis	0.000407	0.0017	CcSEcCtD
Loxapine—Oedema—Prednisone—multiple sclerosis	0.000406	0.0017	CcSEcCtD
Loxapine—Nausea—Mitoxantrone—multiple sclerosis	0.000405	0.00169	CcSEcCtD
Loxapine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000403	0.00168	CcSEcCtD
Loxapine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000403	0.00168	CcSEcCtD
Loxapine—Fatigue—Dexamethasone—multiple sclerosis	0.000402	0.00168	CcSEcCtD
Loxapine—Fatigue—Betamethasone—multiple sclerosis	0.000402	0.00168	CcSEcCtD
Loxapine—HRH1—brain—multiple sclerosis	0.000401	0.00104	CbGeAlD
Loxapine—Shock—Prednisone—multiple sclerosis	0.0004	0.00167	CcSEcCtD
Loxapine—Nervous system disorder—Prednisone—multiple sclerosis	0.000398	0.00167	CcSEcCtD
Loxapine—Tachycardia—Prednisone—multiple sclerosis	0.000396	0.00166	CcSEcCtD
Loxapine—ADRA2A—brain—multiple sclerosis	0.000394	0.00102	CbGeAlD
Loxapine—Vision blurred—Methotrexate—multiple sclerosis	0.000392	0.00164	CcSEcCtD
Loxapine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000384	0.00161	CcSEcCtD
Loxapine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000384	0.00161	CcSEcCtD
Loxapine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000379	0.00158	CcSEcCtD
Loxapine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000378	0.00158	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—multiple sclerosis	0.000372	0.00156	CcSEcCtD
Loxapine—Dizziness—Prednisolone—multiple sclerosis	0.00037	0.00155	CcSEcCtD
Loxapine—Asthenia—Triamcinolone—multiple sclerosis	0.000369	0.00154	CcSEcCtD
Loxapine—Asthenia—Methylprednisolone—multiple sclerosis	0.000368	0.00154	CcSEcCtD
Loxapine—Insomnia—Prednisone—multiple sclerosis	0.000367	0.00154	CcSEcCtD
Loxapine—Paraesthesia—Prednisone—multiple sclerosis	0.000365	0.00153	CcSEcCtD
Loxapine—Pruritus—Triamcinolone—multiple sclerosis	0.000364	0.00152	CcSEcCtD
Loxapine—Cough—Methotrexate—multiple sclerosis	0.000363	0.00152	CcSEcCtD
Loxapine—Pruritus—Methylprednisolone—multiple sclerosis	0.000363	0.00152	CcSEcCtD
Loxapine—Convulsion—Methotrexate—multiple sclerosis	0.00036	0.00151	CcSEcCtD
Loxapine—Chest pain—Methotrexate—multiple sclerosis	0.000354	0.00148	CcSEcCtD
Loxapine—Rash—Prednisolone—multiple sclerosis	0.000352	0.00147	CcSEcCtD
Loxapine—Dermatitis—Prednisolone—multiple sclerosis	0.000352	0.00147	CcSEcCtD
Loxapine—Fatigue—Prednisone—multiple sclerosis	0.00035	0.00146	CcSEcCtD
Loxapine—Headache—Prednisolone—multiple sclerosis	0.00035	0.00146	CcSEcCtD
Loxapine—Constipation—Prednisone—multiple sclerosis	0.000347	0.00145	CcSEcCtD
Loxapine—Confusional state—Methotrexate—multiple sclerosis	0.000342	0.00143	CcSEcCtD
Loxapine—Dizziness—Triamcinolone—multiple sclerosis	0.00034	0.00142	CcSEcCtD
Loxapine—Dizziness—Methylprednisolone—multiple sclerosis	0.000339	0.00142	CcSEcCtD
Loxapine—HTR2A—brain—multiple sclerosis	0.000335	0.000867	CbGeAlD
Loxapine—Feeling abnormal—Prednisone—multiple sclerosis	0.000335	0.0014	CcSEcCtD
Loxapine—Asthenia—Betamethasone—multiple sclerosis	0.000335	0.0014	CcSEcCtD
Loxapine—Asthenia—Dexamethasone—multiple sclerosis	0.000335	0.0014	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000333	0.00139	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000332	0.00139	CcSEcCtD
Loxapine—Nausea—Prednisolone—multiple sclerosis	0.000332	0.00139	CcSEcCtD
Loxapine—Pruritus—Dexamethasone—multiple sclerosis	0.00033	0.00138	CcSEcCtD
Loxapine—Pruritus—Betamethasone—multiple sclerosis	0.00033	0.00138	CcSEcCtD
Loxapine—Vomiting—Triamcinolone—multiple sclerosis	0.000327	0.00137	CcSEcCtD
Loxapine—Vomiting—Methylprednisolone—multiple sclerosis	0.000326	0.00136	CcSEcCtD
Loxapine—Rash—Triamcinolone—multiple sclerosis	0.000324	0.00136	CcSEcCtD
Loxapine—Dermatitis—Triamcinolone—multiple sclerosis	0.000324	0.00135	CcSEcCtD
Loxapine—Rash—Methylprednisolone—multiple sclerosis	0.000323	0.00135	CcSEcCtD
Loxapine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000323	0.00135	CcSEcCtD
Loxapine—Headache—Triamcinolone—multiple sclerosis	0.000322	0.00135	CcSEcCtD
Loxapine—Headache—Methylprednisolone—multiple sclerosis	0.000321	0.00134	CcSEcCtD
Loxapine—Hypotension—Methotrexate—multiple sclerosis	0.000317	0.00133	CcSEcCtD
Loxapine—Dizziness—Betamethasone—multiple sclerosis	0.000308	0.00129	CcSEcCtD
Loxapine—Dizziness—Dexamethasone—multiple sclerosis	0.000308	0.00129	CcSEcCtD
Loxapine—Insomnia—Methotrexate—multiple sclerosis	0.000307	0.00128	CcSEcCtD
Loxapine—Nausea—Triamcinolone—multiple sclerosis	0.000305	0.00128	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—multiple sclerosis	0.000305	0.00127	CcSEcCtD
Loxapine—Nausea—Methylprednisolone—multiple sclerosis	0.000305	0.00127	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—multiple sclerosis	0.000303	0.00127	CcSEcCtD
Loxapine—Somnolence—Methotrexate—multiple sclerosis	0.000302	0.00126	CcSEcCtD
Loxapine—Hypersensitivity—Prednisone—multiple sclerosis	0.000299	0.00125	CcSEcCtD
Loxapine—Vomiting—Betamethasone—multiple sclerosis	0.000297	0.00124	CcSEcCtD
Loxapine—Vomiting—Dexamethasone—multiple sclerosis	0.000297	0.00124	CcSEcCtD
Loxapine—Rash—Betamethasone—multiple sclerosis	0.000294	0.00123	CcSEcCtD
Loxapine—Rash—Dexamethasone—multiple sclerosis	0.000294	0.00123	CcSEcCtD
Loxapine—Dermatitis—Betamethasone—multiple sclerosis	0.000294	0.00123	CcSEcCtD
Loxapine—Dermatitis—Dexamethasone—multiple sclerosis	0.000294	0.00123	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000293	0.00123	CcSEcCtD
Loxapine—Fatigue—Methotrexate—multiple sclerosis	0.000293	0.00122	CcSEcCtD
Loxapine—Headache—Dexamethasone—multiple sclerosis	0.000292	0.00122	CcSEcCtD
Loxapine—Headache—Betamethasone—multiple sclerosis	0.000292	0.00122	CcSEcCtD
Loxapine—Asthenia—Prednisone—multiple sclerosis	0.000291	0.00122	CcSEcCtD
Loxapine—Pruritus—Prednisone—multiple sclerosis	0.000287	0.0012	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—multiple sclerosis	0.00028	0.00117	CcSEcCtD
Loxapine—Nausea—Betamethasone—multiple sclerosis	0.000277	0.00116	CcSEcCtD
Loxapine—Nausea—Dexamethasone—multiple sclerosis	0.000277	0.00116	CcSEcCtD
Loxapine—Dizziness—Prednisone—multiple sclerosis	0.000269	0.00112	CcSEcCtD
Loxapine—Vomiting—Prednisone—multiple sclerosis	0.000258	0.00108	CcSEcCtD
Loxapine—Rash—Prednisone—multiple sclerosis	0.000256	0.00107	CcSEcCtD
Loxapine—Dermatitis—Prednisone—multiple sclerosis	0.000256	0.00107	CcSEcCtD
Loxapine—Headache—Prednisone—multiple sclerosis	0.000254	0.00106	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—multiple sclerosis	0.00025	0.00105	CcSEcCtD
Loxapine—Asthenia—Methotrexate—multiple sclerosis	0.000244	0.00102	CcSEcCtD
Loxapine—Nausea—Prednisone—multiple sclerosis	0.000241	0.00101	CcSEcCtD
Loxapine—Pruritus—Methotrexate—multiple sclerosis	0.00024	0.001	CcSEcCtD
Loxapine—Dizziness—Methotrexate—multiple sclerosis	0.000224	0.000939	CcSEcCtD
Loxapine—Vomiting—Methotrexate—multiple sclerosis	0.000216	0.000903	CcSEcCtD
Loxapine—Rash—Methotrexate—multiple sclerosis	0.000214	0.000895	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—multiple sclerosis	0.000214	0.000894	CcSEcCtD
Loxapine—Headache—Methotrexate—multiple sclerosis	0.000213	0.000889	CcSEcCtD
Loxapine—Nausea—Methotrexate—multiple sclerosis	0.000202	0.000843	CcSEcCtD
Loxapine—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	1.48e-05	3.96e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL2—multiple sclerosis	1.48e-05	3.96e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	1.48e-05	3.96e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—MAPK1—multiple sclerosis	1.48e-05	3.96e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—APOE—multiple sclerosis	1.48e-05	3.95e-05	CbGpPWpGaD
Loxapine—HRH4—Signaling Pathways—IL6—multiple sclerosis	1.48e-05	3.95e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	1.48e-05	3.94e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	1.47e-05	3.94e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	1.47e-05	3.93e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.46e-05	3.91e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.46e-05	3.89e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL2—multiple sclerosis	1.45e-05	3.88e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	1.45e-05	3.87e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	1.45e-05	3.86e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.43e-05	3.83e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL2—multiple sclerosis	1.43e-05	3.82e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.43e-05	3.81e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	1.43e-05	3.81e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling by GPCR—IL6—multiple sclerosis	1.42e-05	3.8e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	1.42e-05	3.78e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MMP9—multiple sclerosis	1.41e-05	3.78e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MMP9—multiple sclerosis	1.41e-05	3.77e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL2—multiple sclerosis	1.41e-05	3.77e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—POMC—multiple sclerosis	1.41e-05	3.76e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	1.4e-05	3.75e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling by GPCR—IL6—multiple sclerosis	1.4e-05	3.75e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—ALB—multiple sclerosis	1.4e-05	3.73e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	1.39e-05	3.72e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	1.39e-05	3.71e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.39e-05	3.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CD80—multiple sclerosis	1.38e-05	3.69e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	1.38e-05	3.68e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	1.37e-05	3.67e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	1.37e-05	3.66e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.36e-05	3.64e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.36e-05	3.63e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CD80—multiple sclerosis	1.36e-05	3.63e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CD80—multiple sclerosis	1.35e-05	3.62e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MMP9—multiple sclerosis	1.35e-05	3.61e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL2—multiple sclerosis	1.35e-05	3.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CD80—multiple sclerosis	1.35e-05	3.6e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling by GPCR—IL6—multiple sclerosis	1.34e-05	3.59e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CD80—multiple sclerosis	1.34e-05	3.57e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MMP9—multiple sclerosis	1.33e-05	3.56e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	1.33e-05	3.56e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	1.33e-05	3.55e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	1.32e-05	3.53e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—POMC—multiple sclerosis	1.31e-05	3.51e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—POMC—multiple sclerosis	1.29e-05	3.45e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—POMC—multiple sclerosis	1.29e-05	3.45e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL2—multiple sclerosis	1.29e-05	3.44e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	1.29e-05	3.44e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—IL6—multiple sclerosis	1.29e-05	3.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—POMC—multiple sclerosis	1.29e-05	3.44e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCL2—multiple sclerosis	1.29e-05	3.43e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—ALB—multiple sclerosis	1.28e-05	3.43e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—POMC—multiple sclerosis	1.28e-05	3.42e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling by GPCR—IL6—multiple sclerosis	1.28e-05	3.42e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MMP9—multiple sclerosis	1.28e-05	3.41e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL2—multiple sclerosis	1.27e-05	3.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—POMC—multiple sclerosis	1.27e-05	3.39e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	1.27e-05	3.38e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	1.27e-05	3.38e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	1.26e-05	3.38e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling by GPCR—IL6—multiple sclerosis	1.26e-05	3.37e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCL2—multiple sclerosis	1.26e-05	3.37e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	1.26e-05	3.36e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	1.26e-05	3.36e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—STAT3—multiple sclerosis	1.26e-05	3.36e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—STAT3—multiple sclerosis	1.26e-05	3.36e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	1.25e-05	3.35e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	1.25e-05	3.33e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	1.24e-05	3.32e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	1.24e-05	3.31e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	1.24e-05	3.31e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.24e-05	3.31e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	1.23e-05	3.3e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	1.23e-05	3.29e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	1.23e-05	3.28e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	1.22e-05	3.26e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MMP9—multiple sclerosis	1.22e-05	3.25e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	1.22e-05	3.25e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.21e-05	3.24e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—STAT3—multiple sclerosis	1.2e-05	3.21e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MMP9—multiple sclerosis	1.2e-05	3.21e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—STAT3—multiple sclerosis	1.19e-05	3.17e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	1.18e-05	3.14e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MYC—multiple sclerosis	1.17e-05	3.12e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TYK2—multiple sclerosis	1.17e-05	3.12e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MYC—multiple sclerosis	1.17e-05	3.12e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	1.17e-05	3.11e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TGFB1—multiple sclerosis	1.16e-05	3.11e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MYC—multiple sclerosis	1.16e-05	3.1e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	1.16e-05	3.09e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL2—multiple sclerosis	1.16e-05	3.09e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	1.15e-05	3.07e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	1.15e-05	3.07e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	1.15e-05	3.07e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TYK2—multiple sclerosis	1.15e-05	3.06e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	1.15e-05	3.06e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—IL6—multiple sclerosis	1.15e-05	3.06e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	1.14e-05	3.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	1.14e-05	3.05e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MAPK1—multiple sclerosis	1.14e-05	3.05e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	1.14e-05	3.05e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	1.14e-05	3.04e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—IL6—multiple sclerosis	1.14e-05	3.04e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—STAT3—multiple sclerosis	1.14e-05	3.03e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MYC—multiple sclerosis	1.14e-05	3.03e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	1.13e-05	3.03e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	1.13e-05	3.03e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	1.13e-05	3.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.13e-05	3.01e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	1.12e-05	3e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MYC—multiple sclerosis	1.12e-05	2.99e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	1.11e-05	2.98e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	1.11e-05	2.97e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL2—multiple sclerosis	1.11e-05	2.96e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MYC—multiple sclerosis	1.1e-05	2.94e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	1.1e-05	2.94e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL2—multiple sclerosis	1.1e-05	2.94e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TGFB1—multiple sclerosis	1.1e-05	2.94e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	1.1e-05	2.93e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	1.09e-05	2.92e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	1.09e-05	2.92e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	1.08e-05	2.9e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—STAT3—multiple sclerosis	1.08e-05	2.89e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MAPK1—multiple sclerosis	1.08e-05	2.88e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	1.07e-05	2.86e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STAT3—multiple sclerosis	1.07e-05	2.85e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	1.07e-05	2.85e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—multiple sclerosis	1.06e-05	2.82e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	1.05e-05	2.81e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TGFB1—multiple sclerosis	1.05e-05	2.81e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	1.05e-05	2.8e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	1.05e-05	2.8e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	1.04e-05	2.79e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	1.04e-05	2.78e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MAPK1—multiple sclerosis	1.03e-05	2.76e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	1.01e-05	2.71e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—multiple sclerosis	1.01e-05	2.69e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	1e-05	2.68e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	9.97e-06	2.66e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—multiple sclerosis	9.93e-06	2.65e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	9.9e-06	2.65e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	9.84e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	9.73e-06	2.6e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—multiple sclerosis	9.71e-06	2.59e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	9.71e-06	2.59e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—IL6—multiple sclerosis	9.66e-06	2.58e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	9.64e-06	2.58e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—multiple sclerosis	9.56e-06	2.55e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—multiple sclerosis	9.54e-06	2.55e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	9.51e-06	2.54e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—multiple sclerosis	9.51e-06	2.54e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—IL6—multiple sclerosis	9.49e-06	2.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—multiple sclerosis	9.48e-06	2.53e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	9.46e-06	2.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	9.43e-06	2.52e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—multiple sclerosis	9.38e-06	2.51e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	9.36e-06	2.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	9.34e-06	2.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	9.31e-06	2.49e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	9.31e-06	2.49e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	9.26e-06	2.47e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—multiple sclerosis	9.19e-06	2.46e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	9.05e-06	2.42e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—multiple sclerosis	9.04e-06	2.42e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—multiple sclerosis	9.03e-06	2.41e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	9.02e-06	2.41e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	9.01e-06	2.41e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	9e-06	2.4e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	8.97e-06	2.4e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	8.96e-06	2.39e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	8.94e-06	2.39e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	8.88e-06	2.37e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	8.87e-06	2.37e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	8.86e-06	2.37e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	8.85e-06	2.36e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—multiple sclerosis	8.78e-06	2.35e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—multiple sclerosis	8.78e-06	2.34e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	8.77e-06	2.34e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—multiple sclerosis	8.72e-06	2.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	8.7e-06	2.32e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	8.65e-06	2.31e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—multiple sclerosis	8.65e-06	2.31e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	8.63e-06	2.31e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—multiple sclerosis	8.61e-06	2.3e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	8.59e-06	2.29e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—multiple sclerosis	8.54e-06	2.28e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	8.46e-06	2.26e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	8.42e-06	2.25e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—multiple sclerosis	8.4e-06	2.24e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	8.37e-06	2.24e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	8.35e-06	2.23e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—multiple sclerosis	8.29e-06	2.21e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	8.24e-06	2.2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	8.23e-06	2.2e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	8.22e-06	2.2e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	8.19e-06	2.19e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—multiple sclerosis	8.17e-06	2.18e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	8.06e-06	2.15e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	8.04e-06	2.15e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—multiple sclerosis	8.03e-06	2.14e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	8e-06	2.14e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	7.97e-06	2.13e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—multiple sclerosis	7.94e-06	2.12e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	7.9e-06	2.11e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	7.88e-06	2.1e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—multiple sclerosis	7.6e-06	2.03e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	7.58e-06	2.02e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—multiple sclerosis	7.56e-06	2.02e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—multiple sclerosis	7.47e-06	2e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—multiple sclerosis	7.46e-06	1.99e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—multiple sclerosis	7.46e-06	1.99e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	7.46e-06	1.99e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	7.44e-06	1.99e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—multiple sclerosis	7.43e-06	1.99e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	7.43e-06	1.98e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	7.42e-06	1.98e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—multiple sclerosis	7.41e-06	1.98e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	7.39e-06	1.97e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—multiple sclerosis	7.34e-06	1.96e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	7.32e-06	1.96e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	7.32e-06	1.95e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	7.32e-06	1.95e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	7.31e-06	1.95e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	7.3e-06	1.95e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	7.3e-06	1.95e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	7.27e-06	1.94e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	7.25e-06	1.94e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	7.18e-06	1.92e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	7.16e-06	1.91e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	6.8e-06	1.82e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—multiple sclerosis	6.8e-06	1.82e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	6.78e-06	1.81e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	6.74e-06	1.8e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	6.65e-06	1.78e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—multiple sclerosis	6.5e-06	1.74e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—multiple sclerosis	6.47e-06	1.73e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	6.29e-06	1.68e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	6.19e-06	1.65e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—multiple sclerosis	5.71e-06	1.53e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—multiple sclerosis	5.62e-06	1.5e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—multiple sclerosis	5.61e-06	1.5e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—multiple sclerosis	5.59e-06	1.49e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—multiple sclerosis	5.57e-06	1.49e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—multiple sclerosis	5.52e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	5.5e-06	1.47e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	5.11e-06	1.37e-05	CbGpPWpGaD
